Alimera Sciences (NASDAQ:ALIM) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Alimera Sciences (NASDAQ:ALIM) from a hold rating to a buy rating in a report released on Monday morning.

Separately, Maxim Group began coverage on shares of Alimera Sciences in a research note on Monday, March 25th. They set a buy rating and a $10.00 target price for the company.

Alimera Sciences Stock Performance

NASDAQ ALIM opened at $3.63 on Monday. The firm has a 50-day moving average of $3.71 and a 200-day moving average of $3.63. The company has a debt-to-equity ratio of 1.40, a quick ratio of 2.31 and a current ratio of 2.39. The stock has a market cap of $190.03 million, a PE ratio of -1.68 and a beta of 1.18. Alimera Sciences has a 52-week low of $1.56 and a 52-week high of $4.38.

Alimera Sciences (NASDAQ:ALIM) last posted its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.09). The company had revenue of $26.31 million for the quarter, compared to analyst estimates of $25.10 million. Alimera Sciences had a negative return on equity of 130.90% and a negative net margin of 24.93%. During the same quarter in the prior year, the business posted ($0.54) EPS. On average, sell-side analysts anticipate that Alimera Sciences will post 0.03 EPS for the current year.

Institutional Trading of Alimera Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. AIGH Capital Management LLC acquired a new stake in Alimera Sciences in the 3rd quarter worth about $7,355,000. Stonepine Capital Management LLC acquired a new stake in Alimera Sciences in the 3rd quarter worth about $12,349,000. Finally, Worth Venture Partners LLC acquired a new stake in Alimera Sciences in the 3rd quarter worth about $1,840,000. Institutional investors and hedge funds own 99.83% of the company’s stock.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).